At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 130 enrolled
Drug / intervention
pioglitazonedrug
Likely dose
pioglitazone 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) - Role of Intramyocellular Lipid Content and Mitochondrial Dysfunction in Myocardial Insulin Resistance and Their Correction With Pioglitazone
The University of Texas Health Science Center at San Antonio·interventional·Posted May 1, 2012·Updated Dec 6, 2017
In Brief
A Phase 4 clinical trial evaluating pioglitazone for Type 2 Diabetes and Coronary Heart Disease. Completed, enrolled 130 participants.
Detailed Summary
The purpose of this study is to examine the existence of heart abnormalities in patients with diabetes and the effect of pioglitazone in correcting these abnormalities.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Coronary Heart Disease
Countries--
CollaboratorsTakeda Pharmaceuticals North America, Inc.
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
Primary CompletionDec 2011
First PostedMay 2012
TodayJul 2026
First PostedMay 1, 2012
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 14.2 years ago
Interventions
pioglitazonedrug
45 mg per day for 6 months